The initial success of Viagra undeniably revolutionized the drug landscape, but investing in companies heavily reliant on generic versions presents a uncertain picture. Although early earnings were substantial, the expiration of patents and the emergence of less expensive alternatives have diminished sales. Therefore, a thorough evaluation of ongoi